Corvus Pharmaceuticals (CRVS) said late Thursday that new interim data from a phase 1 clinical trial of soquelitinib to treat moderate to severe atopic dermatitis showed a "favorable" safety and efficacy profile.

The company found "earlier and deeper responses" in group 3, which received 200 milligrams twice a day, compared with groups 1 and 2, which received 100 mg twice daily and 200 mg once daily.

Corvus said that all three groups showed "significant responses" in the soquelitinib treatment groups, compared with placebo for clinically significant endpoints.

Atopic dermatitis is a skin condition characterized by dry, itchy, and inflamed skin.

Shares of the company were up 37% in recent premarket activity Friday.